Your browser is no longer supported. Please, upgrade your browser.
Settings
XPH SPDR S&P Pharmaceuticals ETF daily Stock Chart
XPH [NYSE]
SPDR S&P Pharmaceuticals ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-1.32%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month0.05%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-2.11%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio11.51 Perf Half Y2.94%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year1.30%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range36.58 - 44.50 Perf YTD9.34%
Dividend0.28 P/FCF- EPS past 5Y- ROI- 52W High-3.73% Beta-
Dividend %0.66% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low17.11% ATR0.55
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)51.45 Volatility1.10% 1.28%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.43 Prev Close42.74
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume98.29K Price42.84
Recom- SMA20-0.21% SMA501.54% SMA2002.36% Volume33,144 Change0.23%
Oct-17-17 10:26AM  Neothetics's stock rockets on heavy volume after merger deal MarketWatch
Oct-16-17 12:33PM  President Trump reiterates that drug companies 'getting away with murder' but says not much else MarketWatch
Sep-20-17 11:47AM  Jump In Pet Adoptions Is Good News For Animal Health Stocks Barrons.com
Sep-19-17 05:09PM  ETF Flopper: Repeal and Replace Revived, Sinks Health-Care Stocks Barrons.com
Sep-11-17 07:36AM  Introducing Mercks 2Q17 Immuno-Oncology Blockbuster Market Realist
Sep-04-17 10:36AM  Eli Lillys Cardiovascular Products in 2Q17 Market Realist
Aug-30-17 10:37AM  Performance of Bristol-Myers Squibbs Eliquis in 2Q17 Market Realist
Aug-23-17 09:08AM  Defitelio Continues to Demonstrate Robust Demand Trends in 2017 Market Realist
Aug-21-17 02:36PM  Why Jazz Is Expected to Report a Robust Revenue Growth Rate Market Realist
Aug-11-17 08:42AM  Peregrine Pharmaceuticals laid off one-fifth of its workforce MarketWatch
Aug-07-17 12:10PM  Teva's stock keeps plunging on heavy volume after Morgan Stanley downgrade MarketWatch
09:45AM  Q2 Earnings Fail to Impress Pharma ETF Zacks
Aug-03-17 09:59AM  Three Large Cap Pharma Picks That Can Outperform This Year Barrons.com
07:55AM  Teva's stock plunges on heavy volume after profit miss and slashed outlook MarketWatch
Aug-01-17 07:41AM  Bristol-Myers Squibbs 2Q17 Earnings: Virology Products Market Realist
Jul-31-17 09:39AM  What Trump could do to make Obamacare implode MarketWatch
Jul-28-17 03:36PM  Eli Lillys Business Segments in 2Q17 Market Realist
Jul-26-17 04:35PM  Bristol-Myers Squibbs 2Q17 Estimates: Expect Growth! Market Realist
Jul-24-17 12:35PM  What Analysts Recommend for Eli Lilly ahead of 2Q17 Results Market Realist
Jul-14-17 09:09AM  Understanding Allergans Revenue Stream for 2017 Market Realist
Jul-11-17 10:47AM  This week could be make or break for the GOP health care bill MarketWatch
Jul-10-17 03:10PM  What Lies Ahead for Pharma ETFs in Second Half 2017 Zacks
07:21AM  Kala sets terms of IPO to raise up to $96 million MarketWatch
Jul-07-17 04:07PM  A Look at Pharmaceutical ETFs in 2Q17 Market Realist
Jul-06-17 07:45AM  Egalet's stock plunges toward record low after stock offering plan MarketWatch
Jul-04-17 09:06AM  Performance of Mercks Gardasil and Other Human Vaccines in 1Q17 Market Realist
Jun-29-17 08:28AM  Why did these generic drugs prices jump as much as 85%? MarketWatch
Jun-21-17 01:03PM  Drug stocks surge on report that President Trump plans to ease industry regulations MarketWatch
Jun-20-17 07:36AM  Key Updates on Eli Lillys Jardiance Market Realist
Jun-19-17 07:45AM  Valeant's stock surges after largest shareholder John Paulson elected to board MarketWatch
Jun-08-17 10:36AM  Why Pfizers Products Lost Market Share in 1Q17 Market Realist
Jun-02-17 07:37AM  Performance of Eli Lillys New Products Portfolio in 1Q17 Market Realist
May-30-17 03:35PM  Changes in Johnson & Johnsons Revenue in 1Q17 Market Realist
May-25-17 07:35AM  Mercks Immunology and Cardiovascular Franchise in 1Q17 Market Realist
May-19-17 07:36AM  What Happened to Bristol-Myers Squibbs Opdivo in 1Q17? Market Realist
May-10-17 06:05PM  Behind Allergans US Specialized Therapeutics Segment in 1Q17 Market Realist
May-09-17 07:14AM  Valeant's stock soars after profit beats expectations MarketWatch
May-08-17 05:42PM  ETF Flopper: Biotechnology and Pharmaceuticals Feel the Pain Barrons.com
09:01AM  Mallinckrodt's stock jumps after profit and sales beat MarketWatch
May-02-17 07:37AM  Eli Lillys 1Q17 Earnings: Cialis and Other Cardiovascular Products Market Realist
Apr-28-17 03:35PM  Eli Lillys Business Segments and Their Performance in 1Q17 Market Realist
Apr-26-17 07:37AM  A Look at Bristol-Myers Squibbs Oncology Segment in 1Q17 Market Realist
Apr-21-17 09:06AM  Johnson & Johnsons Consumer Segments 1Q17 Earnings Market Realist
Apr-20-17 11:31AM  Analyst Estimates for Eli Lillys 1Q17 Earnings Market Realist
Apr-14-17 10:36AM  Analysts Ratings for Johnson & Johnson in 1Q17 Market Realist
Apr-11-17 11:29AM  The Hybrid US Healthcare System: An Overview Market Realist
Apr-10-17 07:36AM  How Pfizer Stock Performed in 1Q17 Market Realist
Apr-07-17 06:59PM  ETF Flyers: Pharmaceuticals Barrons.com
Mar-31-17 07:36AM  Analyzing LLYs Cardiovascular Franchises 2016 Performance Market Realist
07:36AM  Analyzing LLYs Cardiovascular Franchises 2016 Performance
Mar-29-17 09:30AM  The Zacks Analyst Blog Highlights: HCA Holdings, Molina Healthcare, SPDR S&P Pharmaceuticals ETF, BioShares Biotechnology Products Fund and The Health Care Select Sector SPDR Fund Zacks
09:30AM  The Zacks Analyst Blog Highlights: HCA Holdings, Molina Healthcare, SPDR S&P Pharmaceuticals ETF, BioShares Biotechnology Products Fund and The Health Care Select Sector SPDR Fund at Investopedia
Mar-27-17 06:04PM  ETF Flyer: Healthcare Stocks Continue To Dance On the Grave Of The Failed GOP Bill Barrons.com
06:04PM  ETF Flyer: Healthcare Stocks Continue To Dance On the Grave Of The Failed GOP Bill at Barrons.com
Mar-20-17 10:22AM  Trump, Biogen and Amgen Hammer Healthcare ETFs Zacks
Mar-16-17 03:05PM  Analyzing Bristol-Myers Squibbs 2016 Performance Market Realist
03:05PM  Analyzing Bristol-Myers Squibbs 2016 Performance
Mar-15-17 04:33PM  Should You Buy Pharma ETFs Now? Zacks
09:05AM  Johnson & Johnsons Financial Guidance for 2017 Market Realist
09:05AM  Johnson & Johnsons Financial Guidance for 2017
Mar-14-17 04:03PM  Aurinias stock plunges after big share offering at deep discount MarketWatch
04:03PM  Aurinias stock plunges after big share offering at deep discount at MarketWatch
Mar-08-17 10:07AM  Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs Zacks
Mar-07-17 04:05PM  Stocks Fall for Day Two as Trump Targets Health Care Sector
02:24PM  Stock market loses ground as energy shares weigh at MarketWatch
09:16AM  Pharma and biotech stocks slump after President Trump tweets about lowering drug prices at MarketWatch
Mar-06-17 10:36AM  How Mylan Is Valued after 4Q16 Earnings
Mar-01-17 04:14PM  Best & Worst ETFs of February 2017
01:24PM  Investors have stopped believing Trumps drug price threats at MarketWatch
08:23AM  Bernie Sanders has some new allies in fight to bring Canadian drugs to the U.S. at MarketWatch
Feb-27-17 08:22AM  Pieris Pharmaceuticals' stock soars after exclusive license deal with Japan's ASKA at MarketWatch
07:32AM  La Jolla Pharmaceutical's stock rockets in active trade after positive trial results at MarketWatch
Feb-24-17 10:38AM  Eli Lilly & Co.s Cardiovascular Franchise
Feb-23-17 07:47AM  Gardasil Driving Merck & Co.s Vaccines Business in 4Q16
Feb-07-17 04:42PM  Drug stocks dip after Spicer affirms Trumps stance on cutting costs at MarketWatch
Feb-06-17 09:55AM  Q4 Earnings Faring Well for Pharma ETFs
Jan-26-17 09:06AM  What to Expect from Eli Lillys Cardiovascular Franchise in 4Q16
Jan-20-17 09:59AM  A.M. Funds Roundup: Investors Buy Volatility ETFs, Exit Equity ETFs Ahead Of Inauguration, at Barrons.com
Jan-19-17 04:06PM  What Lies Ahead for Pharma ETFs?
Jan-17-17 11:16AM  Biotech ETFs: When Will The Pain End? at Barrons.com
Jan-12-17 12:01PM  Biotech ETFs Continue To Bleed at Barrons.com
12:00PM  Trump's First Press Conference Puts These ETFs in Focus
10:37AM  Mylans Specialty Segment: The Effect of Falling EpiPen Sales
Jan-11-17 04:30PM  The Biggest Loser: Endo International Tumbles 8.6% at Barrons.com
01:03PM  2 Stocks For a Trump-ed Up Pharma Market at Barrons.com
12:09PM  Biotech, Pharma ETFs Sink; Trump Promises "Bidding Procedures" at Barrons.com
Dec-20-16 08:19AM  Tesaro NDA for ovarian cancer treatment granted priority review at MarketWatch
07:36AM  It Was a Successful 3Q16 for Horizon Pharmas Primary Care
Dec-16-16 08:37AM  Mylan's first generic EpiPen launches at less than half the cost of branded version at MarketWatch
Dec-14-16 08:05AM  Loss of Patent Protection to Drag Pfizers Top Line
Dec-12-16 09:36AM  Ibrance Is the Only Registered CDK 4/6 Inhibitor for Breast Cancer
Dec-09-16 07:26AM  Express Scripts stock rocked by tweets from short seller Andrew Left at MarketWatch
Dec-08-16 03:00PM  Biotech & Pharma ETFs to Suffer in 2017 Too?
01:43PM  Express Scripts' stock dives after short seller Andrew Left takes aim at MarketWatch
Dec-07-16 02:11PM  President-elect Trumps promise to bring down drug prices sends biotech and pharma ETFs slumping at MarketWatch
12:40PM  Trumps Drug Price Comments Weigh on Biotech and Pharma ETFs and Shares at 24/7 Wall St.
11:31AM  Biotech ETFs: So Much For The Trump Bounce at Barrons.com
Dec-05-16 11:05AM  Inside Mercks Profitability after 3Q16
Dec-02-16 04:05PM  Two Nano-Cap Pharma Stocks To Watch Right Now at Insider Monkey
10:49AM  5 Secret Santa ETFs & Stocks for Your Portfolio
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.